Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

AZD6140

Known as: AZD 6140, AZD-6140 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Ticagrelor

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2009
Review
2009
Ticagrelor: The First Reversibly Binding Oral P2Y12 Receptor Antagonist
Ticagrelor (AZD6140) is the first reversibly binding oral P2Y12 receptor antagonist that blocks ADP-induced platelet aggregation… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Highly Cited
2009
Highly Cited
2009
Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADP‐induced receptor signaling and platelet aggregation
Summary.  Background: P2Y12 plays an important role in regulating platelet aggregation and function. This receptor is the primary… Expand
Review
2008
Review
2008
P2 receptors, platelet function and pharmacological implications.
  • C. Gachet
  • Thrombosis and haemostasis
  • 2008
    • Corpus ID: 6996844
ADP and ATP play a crucial role in platelet activation and their receptors are potential targets for antithrombotic drugs. The… Expand
  • figure 1
Review
2008
Review
2008
Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
The conventional management of thrombotic and cardiovascular disorders is based on the use of heparin, oral anticoagulants, and… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Highly Cited
2007
Highly Cited
2007
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
OBJECTIVES In a substudy of DISPERSE (Dose confIrmation Study assessing anti-Platelet Effects of AZD6140 vs. clopidogRel in non… Expand
Highly Cited
2007
Highly Cited
2007
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute…
OBJECTIVES Our goal was to compare the safety and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Highly Cited
2007
Highly Cited
2007
From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis.
Starting from adenosine triphosphate (ATP), the identification of a novel series of P2Y(12) receptor antagonists and exploitation… Expand
Review
2007
Review
2007
Clopidogrel resistance?
Clopidogrel is an effective inhibitor of platelet activation and aggregation due to its selective and irreversible blockade of… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Highly Cited
2006
Highly Cited
2006
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.
AIMS This double-blind, parallel-group study was conducted to assess the pharmacodynamics, pharmacokinetics, and safety of… Expand
Review
2005
Review
2005
Preclinical and clinical studies with selective reversible direct P2Y12 antagonists.
An important role for adenosine diphosphate (ADP)-induced platelet activation and aggregation was proposed more than 40 years ago… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE